Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6203975 | 1.00 | RAB9A (0.39) | RAB9AHSD11B1LMNAKDM4ECASP1 | |
| SCHEMBL6801335 | 0.84 | HSD11B1 (0.38) | HSD11B1LMNAGRIN1GRIN2AGRIN2B | |
| SCHEMBL6801337 | 0.84 | HSD11B1 (0.38) | HSD11B1LMNAGRIN1GRIN2AGRIN2B | |
| SCHEMBL8486339 | 0.83 | L3MBTL1 (0.49) | LMNAMAPTMDM2ALDH1A1L3MBTL1 | |
| SCHEMBL8486337 | 0.83 | L3MBTL1 (0.49) | LMNAMAPTMDM2ALDH1A1L3MBTL1 | |
| SCHEMBL8484168 | 0.81 | L3MBTL1 (0.50) | LMNAMAPTMDM2ALDH1A1L3MBTL1 | |
| SCHEMBL8484165 | 0.81 | L3MBTL1 (0.50) | LMNAMAPTMDM2ALDH1A1L3MBTL1 | |
| SCHEMBL8486156 | 0.76 | L3MBTL1 (0.52) | RAB9ALMNAMAPTMDM2ALDH1A1 | |
| SCHEMBL8486160 | 0.76 | L3MBTL1 (0.52) | RAB9ALMNAMAPTMDM2ALDH1A1 | |
| SCHEMBL12000497 | 0.75 | OPRM1 (0.45) | HSD11B1LMNAMAPTALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501800-A1 | BOMBESIN ANTAGONISTS | Warner-Lambert Company LLC (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040063643-A1 | Bombesin antagonists | PFIZER INC. | 2004-04-01 | — | — | US | disclosed |
| WO-2003092670-A1 | BOMBESIN ANTAGONISTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063643-A1 | Bombesin antagonists | BRS3, NPSR1, GNRHR | RAB9A 1163/4885HSD11B1 602/4885LMNA 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.